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Abstract
Background: It has been suggested that, in the human protein-protein interaction network, changes of
co-expression between highly connected proteins ("hub”) and their interaction neighbours might have important
roles in cancer metastasis and be predictive disease signatures for patient outcome. However, for a cancer, such
disease signatures identified from different studies have little overlap.
Results: Here, we propose a systemic approach to evaluate the reproducibility of disease signatures at multiple
levels, on the basis of some statistically testable biological models. Using two datasets for breast cancer metastasis,
we showed that different signature hubs identified from different studies were highly consistent in terms of
significantly sharing interaction neighbours and displaying consistent co-expression changes with their overlapping
neighbours, whereas the shared interaction neighbours were significantly over-represented with known cancer
genes and enriched in pathways deregulated in breast cancer pathogenesis. Then, we showed that the signature
hubs identified from the two datasets were highly reproducible at the protein interaction and pathway levels in
three other independent datasets.
Conclusions: Our results provide a possible biological model that different signature hubs altered in different
patient cohorts could disturb the same pathways associated with cancer metastasis through their interaction
neighbours.
Background
Analysis of gene expression patterns in cancers has greatly
enhanced our understanding of the biology of cancer and
provided a way to improve the prediction of many cancers.
For example, many signature genes have been extracted
from microarray data to predict the outcome of breast
cancer [1-4]. However, for a particular disease, signature
genes identified from different studies are usually highly
inconsistent, raising doubts about the biological signifi-
cance or clinical implication of the signatures identified
[5-7]. In attempts to tackle this problem, many approaches
have been proposed for the extraction of network-based
disease signatures based on protein-protein interaction
(PPI) data. Notably, because the PPI data is a union of the
interactions activated under various conditions, and cur-
rently includes a lot of false positives, it alone can provide
limited information for discriminating interactions in dif-
ferent biological pathways such as signal transduction
pathways. On the other hand, considering that gene
expression is sensitive to disease conditions, it is reason-
able to combine gene expression data with PPI data to
measure the’activity’of PPI subnetworks in response to the
investigated conditions and such subnetworks are often
suggestive of functional signaling cascades, metabolic
pathways and molecular complexes that are associated
with the disease phenotypes [8-11]. For example, Chuang
et al. identified PPI subnetworks with coherent gene
expressions as disease signatures that were suggested to be
more accurate than single gene signatures for predicting
breast cancer metastasis [11]. However, the subnetworks
identified from different datasets were still highly inconsis-
tent [12]. Recently, Taylor et al. searched for changes in
the global modularity of the human interactome and
found that patients who survived breast cancer had an
organization of the PPI network different from that in
patients who died of the illness [13]. Specifically, they sug-
gested that “hub” proteins with altered co-expression
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robust signatures to predict cancer outcome. However, as
shown here, such signature hubs selected from different
studies for breast cancer metastasis have little overlap.
This irreproducibility problem is usually attributed to
deficiency in experimental designs, different platforms
and statistical analyses of disease signatures [14,15].
However, it is very likely that the inconsistency of dis-
ease signatures discovered from different cancer samples
for a particular cancer might reflect the biological varia-
tion and heterogeneity of the cancer [5,16]. It is becom-
ing increasingly clear that, for a particular cancer,
genetic and epigenetic changes in different patients are
extremely heterogeneous. Especially, as demonstrated in
recent high-throughput screens of somatic mutation of
genes in cancer genomes, the vast majority of gene
mutations are different among patients with a particular
cancer [17-22]. It is also becoming clear that diverse
molecular changes in cancers might actually be consis-
tent in some essential cellular functions (hallmarks)
whose alterations might collectively dictate malignant
growth for almost all human cancers [23,24]. Therefore,
it is reasonable to design scores to evaluate the reprodu-
cibility of disease signatures of cancers at multiple levels
based on some biological assumptions (or molecular
models), taking into account functional relations
between the disease signatures such as expression corre-
lation [16] and functional similarity [25]. If a score is
significantly higher than expected by chance, it provides
statistical evidence that the underlying model could cor-
rectly explain a large fraction of diverse but functionally
related disease signatures. In this sense, the biological
assumptions for designing the scores are testable.
Here, we propose a systemic approach to evaluate the
reproducibility of network-based disease signatures
derived for a particular cancer, taking into account their
functional relations. Specifically, we evaluated the repro-
ducibility of signature hubs for characterizing the
changes of global modularity of the human interactome
for breast cancer metastasis [13]. First, based on the
assumption that proteins with similar interaction neigh-
bours are likely to have similar biological functions
[26,27], we proposed a topological overlap score, the
percentage of overlap based on topology similarity
(POT) score, to measure the reproducibility of signature
hubs detected in different datasets. Using the POT
score, we found signature hubs detected in two datasets
for breast cancer metastasis were highly consistent in
terms of frequently sharing neighbourhood proteins in
the human PPI network and displaying consistent
co-expression changes with the overlapping neighbours.
Then, we showed that the interaction neighbour pro-
teins shared by the two lists of signature hubs from the
two datasets tended to be cancer susceptibility genes
and affect some pathways known to be associated with
breast cancer pathogenesis, indicating that these path-
ways might have important diagnostic and therapeutic
implications. Finally, we proved that these results were
highly reproducible in three other independent datasets
for breast cancer metastasis.
Results
Network topology consistency of the hub protein lists
We first searched for signature hubs whose co-
expressions with their interacting partners were signifi-
cantly different between patients labelled non-metastatic
and metastatic. We used the method proposed by
Taylor et al. [13], as described briefly in Methods,i nt h e
dataset (the Wang dataset) compiled by Wang et al.
[28] and in the dataset (the Desmedt dataset) compiled
by Desmedt et al. [29]. Here, we did not apply the FDR
control at the step of finding signature hubs because the
statistical powers of most multiple test adjustment
methods are decreased in the presence of wide and cor-
related expression changes of genes in cancers [30,31].
Instead, we used a P value of 0.01 to find candidate sig-
nature hubs, as in the work by Taylor et al.[ 1 3 ] .W i t h
P < 0.01, we identified a total of 65 and 72 signature
hubs in the Wang dataset and Desmedt dataset, respec-
tively (See Additional file 1 - T a b l eS 1f o rt h es i g n a t u r e
hubs.). Only 4 signature hubs appeared in both datasets
and the percentage of overlaps (PO) score of the hub
lists was only 5.9%. Thus, at the level of individual pro-
teins, the signature hubs detected in different studies
were extremely inconsistent, although the PO score was
significantly larger than expected by chance alone
(hypergeometric test P = 0.027).
Then, we evaluated the reproducibility of two lists of
signature hubs by the POT score which measures the
percentage of overlapped interaction neighbours of sig-
nature hubs extracted from different studies (see Meth-
ods). First, by the hypergeometric distribution model,
with FDR < 0.05, we tested whether the interaction
neighbours of a hub in a list overlapped significantly
with the neighbours of at least one of the hubs in
another list. Then, considering that signature hubs with
significant neighbourhood overlaps might have similar
functional roles, we calcula t e dt h eP O Ts c o r ef o rt w o
lists of signature hubs. The POT score between the lists
of signature hubs extracted from the Wang dataset and
the Desmedt dataset was as high as 73%.
Next, we did three random experiments to test
whether the increased overlap might be introduced by
some factors irrelevant to the disease status. First, for
each dataset, we assigned phenotype labels randomly to
patients to generate expression data with the same cor-
relation structure as the original dataset, and then
searched for signature hubs in the PPI network by the
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information was randomised, the detected signature
hubs should be irrelevant to disease status. Repeating
this process 1000 times, we found the average of the
POT scores for the random pairs of protein lists was
41%, which was significantly smaller than the score
(73%) observed with the real data (P < 0.005). Second,
we tested whether the increased reproducibility might
be due to the network topology. From the same PPI net-
work, we randomly selected 1000 pairs of protein lists
with the same lengths as the signature hub lists and
then computed their POT scores. The average of the
POT scores for these random pairs of protein lists was
44%, which was significantly smaller than that observed
(P < 0.005). Third, we tested whether the high level of
reproducibility might be due to the high degrees (num-
bers of interaction partners) of signature hubs. Using a
local rewiring algorithm [32], we produced 1000 random
PPI networks in each of which all proteins had exactly
the same connectivity as in the original PPI network
and the choice of their interaction partners was random.
Then, from each random network we selected the pairs
of hub lists that had exactly the same lengths and
degree distributions as the two lists of signature hubs
extracted from the actual PPI network. Then, we recal-
culated the POT score for this random pair of hub lists.
This process was repeated 1000 times. The average POT
score for 1000 pairs of random hub lists was 42%, signif-
icantly smaller than that observed (P < 0.005).
Both false negatives and false positives are concerned
for the PPI data quality [33,34]. To tackle the low cover-
age problem introduced by false negatives, we integrated
8 databases to generate a large PPI network for our
study. To reduce the effect of false positives, we also
used a small PPI network which contained only the
hand-curated PPI interaction data from OPHID [35]
and MINT [36]. The POT score was decreased a little
to 62% due to the smaller network size based on this
PPI dataset. However, the POT score was significantly
higher than those (20%, 29% and 17%) based on each of
the three random experiments described above (P <
0.005), respectively. Two PPI networks generated similar
POT scores, suggesting that our results were rather
robust against false negatives and false positives in the
PPI data.
Pathway consistency of the hub protein lists
If two signature hubs share many interaction neighbour
proteins, then they might participate in the same or
similar functions [26,27]. To reveal the consistency of
signature hub lists at the pathway level, for each signa-
ture hub identified from each dataset, we analysed the
enrichment of its interaction neighbours in pathways
collected in the Kyoto Encyclopaedia of Genes and
Genomes (KEGG) [37] (see Methods). With FDR < 0.01,
we found that 34 pathways were enriched significantly
with the neighbours of at least one of the signature
hubs detected in the Desmedt dataset, among which
26 pathways were included in the 38 significant path-
ways detected in the Wang dataset (See Additional
file 1-Table S2 for the list of 26 pathways.). Notably,
among the other 12 pathways detected in the Wang
dataset but not in the Desmedt dataset, 11 were margin-
ally significant in the Desmedt dataset with P <0 . 0 5 .
Similarly, among the 8 pathways detected in the
Desmedt dataset but not in the Wang dataset, 6
were marginally significant in the Wang dataset with
P < 0.05. Thus, some inconsistency between the two
datasets might come from a reduction of the statistical
power by using the stringent FDR control for adjusting
multiple tests when the multiple tests are not indepen-
dent of each other [30,31].
We did a random experiment to test the significance
of the high concordance of pathway enrichment (see
Methods). First, we took the 38 pathways identified from
the Wang dataset as the gold standard. From each of
the random networks produced by a local rewiring algo-
rithm [32], we extracted a random hub list of the same
length and degree distribution with the list of signature
hubs identified from the Desmedt dataset. Then, we
detected the pathways enriched with the neighbours of
random hubs and compared them with the gold stan-
dard. Repeating this process 1000 times, we found the
average number of overlapping pathways was 1, signifi-
cantly fewer than the 26 overlaps observed in the real
data (P < 0.001). The result was the same when taking
the pathways detected from the Desmedt dataset as the
gold standard.
The 26 pathways detected in both datasets included
many pathways known to be deregulated in breast can-
cer pathogenesis, such as cell cycle, apoptosis,
J a k - S T A T ,M A P K ,E r b B ,W n ta n dP 5 3s i g n a l l i n gp a t h -
ways [38]. Among these 26 pathways, there were 191 and
238 interaction neighbours of the signature hubs identi-
fied from the Wang and Desmedt datasets, respectively,
and they shared 114 proteins, which was significantly
more than expected by chance alone (hypergeometric
test P <2 . 2×1 0
-16). These common interaction neigh-
bour proteins might have important roles in cancer. To
test this, we assembled a list of 427 cancer susceptibility
genes from the Cancer Gene Census database [39] and
found 50 out of 114 neighbour proteins were known can-
cer proteins (hypergeometric test P=6×1 0
-4). When
using the 685 genes collected in our F-census database
[25], 100 out of 114 neighbour proteins were included
(hypergeometric test with P < 2.2 × 10
-16).
The above results suggested that the two lists of signa-
ture hubs might affect the same pathways. In one situation,
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could be affected by the co-expression changes of different
signature hubs with the same set of neighbours enriched in
this pathway. For example (Figure 1a), the interleukins IL2
and IL6 were identified as signature hubs from the Wang
and Desmedt datasets separately and their overlapped
neighbours were enriched in the Jak-STAT signalling path-
way. Thus, changes of co-expression of these shared neigh-
bours with either IL2 or IL6 might disrupt the Jak-STAT
signalling pathway and contribute to the progression of
cancer [40]. For another example (Figure 1b), 6 signature
hubs identified from the Wang dataset and another 3 sig-
nature hubs identified from the Dsemedt dataset are all
subunits of a ribosome complex for protein biosynthesis.
They share other subunits as interaction neighbours and
their deregulation might be associated with cell growth and
proliferation [41]. In another situation, a cancer-associated
pathway could be affected by changes of different signature
hubs interacting with different sets of neighbours that were
separately enriched in this pathway. For example (Figure
1c), proteins DUSP3 with degree 18 and CAD with degree
39 were identified as signature hubs in the Wang and Des-
medt datasets separately. The neighbours of each of these
two proteins were enriched in the MAPK signalling path-
way associated with cancer metastasis [42], but their neigh-
bours shared only 1 protein. It has been suggested that
DUSP3 can negatively regulate members of the MAP
kinase superfamily (MAPK) [43], while the deregulation of
CAD proteins might be associated with activation of the
MAPK cascade [44]. Notably, this functional relation
between two signature hubs was not reflected by the POT
score, which considers only overlapping neighbours
between the signature hubs (see Discussion).
Co-expression consistency of the hub proteins lists
Considering that a signature hub disturbs functions
through differential co-expression with their interaction
neighbours [13], we further assumed that two function-
ally similar hubs should display consistent co-expression
changes with their overlapping neighbours across differ-
ent datasets [45,46]. Therefore, for two hubs detected
from two datasets separately, we additionally tested the
consistency of the directions of their correlations with
the shared neighbours across the datasets by the
Bernoulli distribution model (see Methods).
With the co-expression restriction, for Wang and
Desmedt dataset, the POT score (denoted as POG-e
score) decreased a little from 73% to 67%, largely
explainable when considering that any extra restriction
m a ym i s ss o m et r u er e l a t i o n s .O nt h eo t h e rh a n d ,t h e
random POT-e score decreased greatly from 44% to
26%. The results suggested that signature hubs sharing
neighbours were significantly consistent in the change
directions of correlations with their shared neighbors.
For example, from the Wang and Desmedt datasets
separately, the interleukins IL2 and IL6 were identified
as signature hubs and their 6 overlapped neighbours
were enriched in the Jak-STAT signaling pathway. In
both Wang and Desmedt datasets, the expressions of
IL2 and IL6 were both positively correlated with the
expressions of these shared neighbours in non-meta-
static patients, but negatively correlated with the expres-
sions of the shared neighbours in metastatic patients.
These results suggest that Jak-STAT signaling pathway
could be perturbed by the disruption of co-expressions
of either IL2 or IL6 with the shared neighbours during
the breast cancer metastasis.
Validation in three independent breast cancer datasets
We validated our results by analyzing three other inde-
pendent datasets for breast cancer metastasis [2,47,48].
For lists of signature hubs extracted from every two
breast cancer datasets, the PO score was less than 4%.
However, the corresponding POT scores took values
ranging from 61% to 75% which were all significantly
larger than expected by chance according to the three
random experiments as described in Methods. Similar
results were observed based on the POT-e score
(P < 0.005, see Additional file 1- Table S3 for details).
For example, 80 signature hubs were identified from
the Vijver dataset, among which only 4 and 1 overlapped
with the signature hubs found in the Wang and Desmedt
datasets, respectively. However, the corresponding POT
scores were 64% and 75%, respectively, and they were
both significantly larger than expected by chance
(P < 0.005), according to each of the three random
experiments as described in Methods.N o t a b l y ,a l t h o u g h
the average POT score between the Wang and Vijver
datasets was only 64%, the POT score for the signature
hub list extracted from the Vijver dataset to the signature
hub list extracted from the Wang dataset was 71%, sug-
gesting that many of the signature hubs detected from
the Vijver dataset could be represented by the signature
hubs from the Wang dataset in terms of neighbourhood
similarity. The score in the opposite direction was only
57%, indicating that the samples used in the Vijver data-
set might be insufficient for capturing enough signature
hubs to cover the signature hubs extracted from the
Wang dataset.
According to pathway enrichment analysis, the signature
hubs extracted from the Vijver dataset and those from
both the Wang dataset and the Desmedt dataset were
highly consistent. Among the 26 pathways shared by the
Wang and Desmedt datasets, 19 were included in the 34
pathways identified from the Vijver dataset, significantly
more than expected by chance alone (hypergeometric
test P =5 . 2×1 0
-5). All the other 7 pathways detected in
both the Wang and Desmedt datasets were marginally
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Page 4 of 10Figure 1 Examples of pathways shared by a signature hub from the Wang dataset and a signature hub from the Desmedt dataset.
(a) JAK-STAT signaling pathway; (b) Ribosome complex; (c) MAPK signaling pathway. The yellow and red colors represent proteins (both hubs
and their neighbors) identified from the Wang and Desmedt datasets, respectively. The orange colors represent the overlapped neighbors of
these two hub proteins. Please see the main text for detailed explanation.
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results indicated that these pathways, such as MAPK sig-
naling and apoptosis pathways which were also founded in
other studies [11,49], might be disturbed in the breast
metastatic progression.
The above results confirmed that signature hubs
detected from different datasets for breast cancer metas-
tasis were reproducible in terms of neighbourhood pro-
tein overlap and, more generally, pathway overlap.
Notably, approximately half of the patients in the Vijver
dataset were lymph node-positive and underwent adju-
vant therapy before expression profiling, whereas all
patients in the Wang dataset had lymph node-negative
breast cancer [11]. However, our results indicated that
the two types of samples might have similar molecular
changes at the pathway level.
Discussion
Changes in the global modularity of the human inter-
actome might provide important insights into the mechan-
ism underlying cancer metastasis [13]. As shown in this
study, although signature hubs detected from different stu-
dies for breast cancer metastasis have little overlap, they
are highly consistent in terms of frequently sharing inter-
action proteins and displaying consistent co-expression
changes with their overlapping neighbours, indicating that
they might alter the same pathways through differential
co-expression with their interaction neighbours. To some
extent, this finding is similar to the observation made in
microRNA studies that a cancer pathway could be chan-
ged in cancer cases by either aberration of some cancer
genes or modification of microRNAs regulating these
genes [50]. Recently, using several microarray datasets, Li
et al. identified gene signature modules with high predic-
tive accuracy for breast cancer metastasis [49]. These
modules contained two parts: a set of signature genes that
are dynamically modulated between ‘high-risk’ and ‘low-
risk’ patients and a unique set of cancer driver-mutating
genes that are the direct protein interacting partners of
the signature genes. At the conceptual level, their results
also suggested that, despite low overlap, disease signatures
detected from different datasets may reflect consistent
function disruptions. Especially, many modules identified
by Li et al., such as cell cycle, apoptosis and immune
response, were functionally consistent with our KEGG
pathways enriched with proteins targeted by different sig-
nature hubs.
The POT score proposed in this paper considers the
functional concordance between signature hubs only
according to their overlapping neighbours. The signifi-
cantly high POT scores between signature hubs derived
from different studies for breast cancer metastasis indi-
cates that the biological assumption included in this
score could explain a large fraction of diverse signature
hubs. However, the POT scores were only about 70%
for the five datasets in this study and some inconsistent
signature hubs could not be explained by this model.
One explanation is that the incomplete PPI data might
be insufficient for capturing all functional links among
signature hubs. Another possibility is that there might
be other molecular models that can explain the remain-
ing inconsistent discoveries. For example, as illustrated
by a case presented in Results, two signature hubs with
non-overlapping neighbours might be functionally con-
sistent if their neighbours are enriched separately in the
same pathway, but such a functional relation is not
measured by the POT score. Principally, we could
further consider this and other possible relations of sig-
nature hubs to reveal the consistency of signature hub
lists. For example, we could evaluate the consistency of
signature hub lists at the pathway level by counting
overlaps of the enrichment pathways associated with
different signature hub lists. However, such a pathway
level analysis might have only a limited application
scope because many proteins have not been annotated
to current pathway databases such as KEGG used in
this study. The limited annotation can reduce the
power of finding true enrichment pathways and intro-
duce some inconsistency [11]. More problematically,
pathways defined in current databases are often incon-
sistent and their boundaries are unclear [51]. For exam-
ple, it is possible that a pathway documented in a
pathway database consists of several sub-pathways, and
only alterations of genes within a sub-pathway have the
same or a similar role in cancer development, and the
genes within the other sub-pathways might be irrelevant
to, or have other roles, in the disease mechanism. In
such a situation, it would be ambiguous if we consider
two signature hubs as functionally equivalent (reprodu-
cible) when they are associated with different parts of
the pathway through their interaction proteins. Thus, to
interpret the consistency of signature hubs at the path-
way level, we need to determine pathways or their sub-
pathways that are most relevant to a disease. Compared
with KEGG and other pathway databases, Gene Ontol-
o g y( G O )[ 5 2 ]c o u l dh e l pu st a c k l et h i sp r o b l e mt o
some degree because it describes biological functions
from general to specific in a hierarchy. However, cur-
rently, it is still a difficult task to treat the redundant
annotations in GO properly [53,54] and this problem
deserves future research efforts [51,55]. Thus, currently,
the pathway analysis can only partially support the POT
score analysis. When the pathway definition and gene
annotation are improved, the pathway analysis will
become an efficient way of explaining inconsistent sig-
natures generated from different studies.
The irreproducibility of molecular signatures detected
for a complex disease is also a common problem in
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biotechnology such as proteomics [56] and metabolo-
mics [57]. Also, it is very likely that the small samples
typically used in current studies of these areas might
reflect the wide and diverse molecular changes in a
complex disease only partially. In general, taking into
account the diverse but correlated molecular changes in
a complex disease such as a cancer, our approach pro-
vides a framework for explaining the reproducibility of
biological findings at the systems biology level. However,
even when we could find functionally consistent disease
signatures from currently available samples, it might
still need thousands of samples to find a few reproduci-
ble individual signatures. Thus, it would be a difficult
task to build a consensus prognostic classifier on the
basis of a few signatures for a complex disease [6]. To
circumvent the difficulty of finding consistent signatures
themselves, we could use some biological pathways
commonly affected by diverse molecular changes as
modular signatures to build robust diagnostic classifiers
[58]. The identification of such clearly defined key path-
ways of cancer metastasis might provide crucial gui-
dance for designing diagnostic classifiers and, perhaps,
appropriate drug combinations [59].
Conclusions
Distant metastases are the major cause of death in cancer
patients. The heterogeneous nature of tumours leads to
different responses from different patients with the same
type of cancer. Therefore, as a sign that two studies have
detected the same result for a disease, it is not necessary
that the signature lists themselves are consistent. They
could be probably tracking a common set of biologic phe-
notype, as we shown here, in protein network, signature
hubs with low reproducibility may actually have similar
functions by interacting with the same sets of neighbour
proteins.
Methods
Datasets
Five datasets of gene expression profiles for breast cancer
metastasis are described in Table 1. Patients who had been
detected metastasis within 5 years during follow-up visits
were assigned to metastatic and the remaining patients
were assigned to non-metastatic. We mainly analyzed the
W a n gd a t a s e t[ 2 8 ]a n dD e s m e d td a t a s e t[ 2 9 ] ,a n dt h e
other three datasets [2,47,48] were used for validation.
The human PPI data were downloaded from MINT
[36], BIND [34], IntAct [60], HPRD [61], MIPS [62], DIP
[63], KEGG (PPrel for protein-protein interactions, ECrel
for enzymes involved in neighboring steps) [64] and
Reactome [65]. To increase the coverage of the PPI net-
work, we pooled together these 8 PPI datasets to con-
struct an integrated PPI network that consists of 101,729
distinct interactions involving 12,372 human proteins
[66]. We restricted our analysis to the 5470 genes encod-
ing proteins in this PPI network and presenting in all five
breast datasets. We also did the analysis using the
OPHID data [35] combined with MINT data [36], which
was the same as the PPI data used by Taylor et al. [13].
The 60 pathways analysed here were collected from
the categories “Environmental Information Processing”
and “Cellular Processes” in the KEGG database [37] at
March 2010.
Selection of signature hubs
As Taylor et al. did, proteins with at least 3 interaction
neighbours in the PPI network were defined as hubs and
used for further study [13]. To determine the difference of
co-expression of a hub with its interaction partners
between metastatic and non-metastatic patients in a data-
set, we calculated the Pearson correlation coefficients
(PCCs) between this hub and its interaction partners in
each patient group and then the absolute difference of the
PCCs between two groups. We randomly permuted
patients in the two groups 1000 times to calculate the ran-
dom distribution of the absolute difference of PCCs
between the groups. Then the real absolute difference of
the PCCs for this hub between patient groups was com-
pared to the random distribution to generate its P value.
Hub proteins with P values < 0.01 were selected as candi-
date signature hubs, also referred to as signature hubs for
short in the text.
Multi-level evaluation of reproducibility
In the following, we describe some scores for measuring
the consistency between signature hubs derived from
different studies for breast cancer metastasis.
At the individual protein level, the consistency of two
lists of signature hubs was measured by the percentage
of overlaps (PO) score [30]. Suppose hub list 1 with
length L1 and list 2 with length L2 share k proteins, then
the POG score from list 1 (or 2) to list 2 (or 1) is:
PO12 1 = kL /
PO21 2 = kL /
The average of the scores in the two directions is:
PO PO PO = 12 21 2 + ()
Based on the assumption that proteins with signifi-
cantly overlapped interaction neighbours are likely to
share the same function [26,27], we designed a score,
named the percentage of overlap based on topology
(POT) similarity score, to measure the consistency of
two lists of signature hubs at the PPI topology similarity
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acting with proteins i and j, respectively, and g is the
number of neighbours shared by these two proteins, the
probability P of observing no fewer than g neighbours
shared by proteins i and j by chance was calculated by
the hypergeometric distribution model as [67]:
P
CC
C
n
i
Nn
mi
N
m
i
g
=− −
−
=
−
∑ 1
0
1
where N is the number of proteins with both PPI and
gene expression data. With FDR < 0.05, the P value was
adjusted by the Bonferroni-Hochberg procedure to
account for multiple tests [68].
Then, let T12 (or T21) be the number of proteins in list
1 (or list 2) whose neighbours are overlapped signifi-
cantly with the neighbours of at least one of the pro-
teins in list 2 (or list 1), then the POT score is defined
as the average of the scores in the two directions:
POT POT POT 12 21 =+ () 2
The score in one direction is:
POT12 12 =+ () kT L 1
and the score in the other direction is:
POT21 21 2 =+ () kT L
The significance of a PO score was calculated as the
probability of observing at least k overlapped proteins by
chance using the hypergeometric probability model [30].
The significance of an observed POT score was assessed
by three random experiments, testing whether the POT
s c o r em i g h tb ed u et o( 1 )t h ec o r r e l a t i o ns t r u c t u r e so f
expression profiles, (2) the PPI network topology or
(3) the degree distribution of the signature hubs. The
details of the experimental procedures are described in
Results.
Both the PO and POT scores are dependent on the
list lengths. In this study, our major objective was to
find consistent results from the hub lists detected from
different studies for a disease and we did not intend to
compare the consistency level of hub lists with different
lengths. Thus, we did not normalize PO or POT scores
as we did in our earlier work [16].
Considering the basic assumption that signature hubs
may disturb functions through differential co-expression
with their interaction neighbours [13], we further assumed
that two functionally similar hubs should display consis-
tent co-expression changes with their overlapping neigh-
bours across different datasets [45,46]. Let n be the
number of neighbours shared by two signature hubs
detected separately from two datasets, and k is the number
of these shared neighbours whose correlation changes
with these two hubs are in the same direction across the
two datasets. Then, the probability P of observing no
fewer than k neighbours with the same directions of corre-
lation changes by chance was calculated by the Bernoulli
distribution model as:
P
n
k
pp
i
k
kn k =−
−
⎛
⎝
⎜
⎞
⎠
⎟ −
=
−
−− + ∑ 1
1
1
0
1
11 ()
With P < 0.05, we calculated the POT score with co-
expression restriction, denoted as POT-e. Then, we did
a random experiment to determine if an observed POT-
e score is significantly larger than expected by chance
w h e nt h ec h a n g ed i r e c t i o n so fc o r r e l a t i o n sb e t w e e n
hubs and their shared neighbours are irrelevant to the
disease conditions. We randomly reassigned phenotype
labels of samples to generate expression data with the
same correlation structure as the original data, and then
recalculated the POT-e score. This process was repeated
1000 times and the P value was calculated as, among
the scores of the 1000 datasets with random pheno-
types, the proportion of the scores exceeding the
observed one.
Pathway enrichment analysis
For each signature hub, we detected pathways enriched
with its interaction neighbours by the hypergeometric
probability model [67]. The P value was adjusted by the
Bonferroni-Hochberg procedure with FDR < 0.01 [68].
Table 1 The five datasets analyzed in this study
Datasets
a No. of Patients metastatic non-metastatic Platforms
Wang dataset [28] 286 106 180 Affymetrix
HG-U133a
Desmedt dataset [29] 198 35 163 Affymetrix HG-U133a
GSE1456 [47] 159 40 119 Affymetrix HG-U133a
GSE3494 [48] 218 37 181 Affymetrix HG-U133a
Vijve dataset [2] 295 78 217 Agilent Hu25K
a Datasets were named according to the authors or GEO numbers.
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Page 8 of 10For a disease, we took the pathways enriched with the
neighbours of signature hubs detected from one dataset
as the gold standard, and then calculated the overlap
with the pathways enriched with the neighbours of
signature hubs detected from another dataset. To test
t h es i g n i f i c a n c eo ft h eo b s e r v e do v e r l a p p i n g ,w ep r o -
duced a random network by using a local rewiring
algorithm [32]. In the random PPI network, all proteins
had exactly the same connectivity as in the original PPI
network and the choice of their interaction partners was
random. Then, from the random network we selected a
random protein list with the same length and degree
distribution as the list of signature hubs identified from
another dataset. Then, with FDR < 0.01, we detected the
pathways enriched with random hubs and compared
them with the gold standard. Repeating this process
1000 times, we calculated the P values for the observed
overlaps.
Additional material
Additional file 1: Supplemental Tables. This file contains Tables S1-S3.
Table S1 Two hub protein lists separately identified from Wang and
Desmedt datasets. Table S2 List of 26 common KEGG pathways. Table S3
POT and POT-e scores for five breast cancer datasets
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